Cargando…

Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

Detalles Bibliográficos
Autores principales:	Guerra, Borja, Martín-Rodríguez, Patricia, Díaz-Chico, Juan Carlos, McNaughton-Smith, Grant, Jiménez-Alonso, Sandra, Hueso-Falcón, Idaira, Montero, Juan Carlos, Blanco, Rosa, León, Javier, Rodríguez-González, Germán, Estévez-Braun, Ana, Pandiella, Atanasio, Díaz-Chico, Bonifacio Nicolás, Fernández-Pérez, Leandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114959/ https://www.ncbi.nlm.nih.gov/pubmed/30181817 http://dx.doi.org/10.18632/oncotarget.26008

Ejemplares similares

CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia
por: Guerra, Borja, et al.
Publicado: (2016)

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
por: Martín-Rodríguez, Patricia, et al.
Publicado: (2019)

Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
por: Spínola-Lasso, Elena, et al.
Publicado: (2023)

Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2014)

Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2018)

Ocoxin oral solution demonstrates antiviral properties in cellular models
por: Pandiella, Atanasio, et al.
Publicado: (2021)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation
por: Centa, Ariana, et al.
Publicado: (2018)

Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review
por: Pandiella-Alonso, Atanasio, et al.
Publicado: (2020)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Antitumoral effect of Ocoxin on acute myeloid leukemia
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2016)

Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin
por: Pérez-Peña, Javier, et al.
Publicado: (2019)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

The Influence of Estrogens on the Biological and Therapeutic Actions of Growth Hormone in the Liver
por: de Mirecki-Garrido, Mercedes, et al.
Publicado: (2012)

Antitumoral effect of Ocoxin in hepatocellular carcinoma
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2017)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Multisite phosphorylation of P-Rex1 by protein kinase C
por: Montero, Juan Carlos, et al.
Publicado: (2016)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
por: Kim, Soo Jung, et al.
Publicado: (2014)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
por: Langabeer, Stephen E., et al.
Publicado: (2023)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
por: Jelinek, Jaroslav, et al.
Publicado: (2011)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia
por: Wang, Xiao, et al.
Publicado: (2023)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Efectividad de la vacuna BNT162b2 para prevenir la COVID-19 en personal sanitario
por: Chico-Sánchez, Pablo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_55hmhbjhfb405a0ilmfj15rbao